Yoel Shoshan, Moshiko Raboh, Michal Ozery-Flato, Vadim Ratner, Alex Golts, Jeffrey K. Weber, Ella Barkan, Simona Rabinovici-Cohen, Sagi Polaczek, Ido Amos, Ben Shapira, Liam Hazan, Matan Ninio, Sivan Ravid, Michael M. Danziger, Yosi Shamay, Sharon Kurant, Joseph A. Morrone, Parthasarathy Suryanarayanan, Michal Rosen-Zvi, Efrat Hexter
Modern AI (Artificial Intelligence) methods offer new opportunities in pharmacology by enabling improved modeling of disease mechanisms and drug action learned from large and heterogeneous biological datasets. A central challenge is developing models that can jointly integrate disparate biomedical modalities. We introduce MAMMAL (Molecular Aligned Multi Modal Architecture and Language), a foundation model for cross-modal learning, designed to address the challenges associated with drug discovery tasks. MAMMAL was pre-trained on 2 billion samples across protein and antibody sequences, small molecules, and gene expression profiles, and supports classification, regression, and generative tasks on cross-modal inputs. Across eleven benchmarks covering multiple stages of the drug discovery pipeline, MAMMAL achieves state-of-the-art performance on nine tasks and competitive results on two. In an antibody-antigen binding benchmark, fine-tuned MAMMAL prediction scores significantly outperform AlphaFold3 confidence scores, used here as a reference proxy for binding likelihood, in five of seven antigen targets. The MAMMAL framework and pretrained models are publicly available to support open and collaborative research.